As of 2026-03-30, the EV/EBITDA ratio of EyePoint Pharmaceuticals Inc (EYPT) is -3.90. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. EYPT's latest enterprise value is 941.05 mil USD. EYPT's TTM EBITDA according to its financial statements is -241.12 mil USD. Dividing these 2 quantities gives us the above EYPT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.4x - 8.8x | 7.9x |
| Forward P/E multiples | 10.4x - 13.9x | 12.5x |
| Fair Price | (28.89) - (24.10) | (28.26) |
| Upside | -331.2% - -292.8% | -326.1% |
| Date | EV/EBITDA |
| 2026-03-25 | -4.09 |
| 2026-03-24 | -3.93 |
| 2026-03-23 | -4.02 |
| 2026-03-20 | -4.16 |
| 2026-03-19 | -4.35 |
| 2026-03-18 | -4.30 |
| 2026-03-17 | -4.39 |
| 2026-03-16 | -4.23 |
| 2026-03-13 | -4.14 |
| 2026-03-12 | -4.43 |
| 2026-03-11 | -4.74 |
| 2026-03-10 | -4.92 |
| 2026-03-09 | -5.00 |
| 2026-03-06 | -5.03 |
| 2026-03-05 | -5.03 |
| 2026-03-04 | -5.81 |
| 2026-03-03 | -5.92 |
| 2026-03-02 | -5.92 |
| 2026-02-27 | -5.65 |
| 2026-02-26 | -5.76 |
| 2026-02-25 | -5.72 |
| 2026-02-24 | -5.48 |
| 2026-02-23 | -5.48 |
| 2026-02-20 | -4.88 |
| 2026-02-19 | -4.66 |
| 2026-02-18 | -4.55 |
| 2026-02-17 | -4.74 |
| 2026-02-13 | -4.06 |
| 2026-02-12 | -4.08 |
| 2026-02-11 | -4.02 |
| 2026-02-10 | -4.32 |
| 2026-02-09 | -4.45 |
| 2026-02-06 | -4.18 |
| 2026-02-05 | -3.98 |
| 2026-02-04 | -3.84 |
| 2026-02-03 | -4.01 |
| 2026-02-02 | -4.18 |
| 2026-01-30 | -4.26 |
| 2026-01-29 | -4.68 |
| 2026-01-28 | -4.78 |
| 2026-01-27 | -5.05 |
| 2026-01-26 | -4.92 |
| 2026-01-23 | -4.83 |
| 2026-01-22 | -5.23 |
| 2026-01-21 | -4.95 |
| 2026-01-20 | -4.95 |
| 2026-01-16 | -4.80 |
| 2026-01-15 | -5.06 |
| 2026-01-14 | -5.09 |
| 2026-01-13 | -5.09 |